Literature DB >> 2879883

Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.

A C Barton, K E Moore, K T Demarest.   

Abstract

The present study was undertaken to compare the abilities of the dopaminergic agonists apomorphine, bromocriptine, and lergotrile to inhibit the synthesis of dopamine (DA) in terminals of nigrostriatal and mesolimbic DA neurons. The in vivo synthesis of DA was estimated by measuring the rate of accumulation of dihydroxyphenylalanine (DOPA) in terminals of nigrostriatal (striatum) and mesolimbic (nucleus accumbens, olfactory tubercle) neurons 30 min after the administration of NSD 1015, a decarboxylase inhibitor. The activation of DA autoreceptors in these regions was evaluated by measuring the abilities of the DA agonists to inhibit DA synthesis in brain regions of rats pretreated with gamma-butyrolactone (GBL). Apomorphine (0.03-1.0 mg/kg for 45 min) and bromocriptine (0.1-10 mg/kg for 90 min) produced dose-dependent decreases in the rate of DA synthesis in all three brain regions of both vehicle- and GBL-treated rats. A time course of the effects of the highest dose of bromocriptine (10 mg/kg), however, demonstrated dramatic regional differences in the ability of this drug to inhibit DA synthesis in saline-versus GBL-pretreated rats. Bromocriptine inhibited the GBL-induced increase in DA synthesis for 6 hours in all regions examined. In the striatum of saline-treated rats the decrease in DA synthesis was evident only at 1.5 hours after bromocriptine administration, while in the nucleus accumbens and olfactory tubercle DA synthesis remained inhibited for 6 hours. By contrast, lergotrile reduced DA synthesis to a similar extent in all three regions for at least 6 hours in both vehicle- and GBL-treated rats. These results suggest that there is no regional difference in the ability of bromocriptine to inhibit DA synthesis via DA autoreceptor mechanisms, but there appear to be differences in postsynaptic DA receptor-mediated mechanisms which regulate nigrostriatal versus mesolimbic DA neurons.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2879883     DOI: 10.1007/bf01244637

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  38 in total

1.  Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gammahydroxybutyric acid.

Authors:  N E Andén; T Magnusson; G Stock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

2.  Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow.

Authors:  G Stock; T Magnusson; N E Andén
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

3.  Inhibition of rat prolactin release by apomorphine in vivo and in vitro.

Authors:  E B Smalstig; B D Sawyer; J A Clemens
Journal:  Endocrinology       Date:  1974-07       Impact factor: 4.736

4.  Differential behavioral and biochemical effects of four dopaminergic agonists.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease.

Authors:  C J Pycock; C D Marsden
Journal:  J Neurol Sci       Date:  1977 Jan-Feb       Impact factor: 3.181

6.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

7.  Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.

Authors:  R W Fuller; K W Perry
Journal:  Biochem Pharmacol       Date:  1982-06-15       Impact factor: 5.858

8.  Accumulation of L-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity.

Authors:  K T Demarest; K E Moore
Journal:  Endocrinology       Date:  1980-02       Impact factor: 4.736

9.  Comparison between lergotrile and bromocriptine in parkinsonism.

Authors:  P F Teychenne; R F Pfeiffer; S M Bern; D McInturff; D B Calne
Journal:  Ann Neurol       Date:  1978-04       Impact factor: 10.422

10.  Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man.

Authors:  M O Thorner; S M Ryan; J A Wass; A Jones; P Bouloux; S Williams; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

View more
  2 in total

1.  Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats.

Authors:  R Pagliari; L Peyrin; O Crambes
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Activation of mesolimbic dopaminergic neurons following central administration of histamine is mediated by H1 receptors.

Authors:  A E Fleckenstein; K J Lookingland; K E Moore
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.